PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aidMary Ann Liebert, Inc.Mary Ann Liebert, Inc.JournalsSearchAlerts
AIDS Research and Human Retroviruses
 
AIDS Res Hum Retroviruses. 2012 October; 28(10): 1265–1272.
PMCID: PMC3448098

Human T-Lymphotropic Virus Type 1 and Type 2 Seroprevalence, Incidence, and Residual Transfusion Risk Among Blood Donors in Brazil During 2007–2009

Anna Bárbara F. Carneiro-Proietti,corresponding author1 Ester C. Sabino,2 Silvana Leão,3 Nanci A. Salles,2 Paula Loureiro,3 Moussa Sarr,4 David Wright,4 Michael Busch,5 Fernando A. Proietti,6 and Edward L. Murphy7, for the NHLBI Retrovirus Epidemiology Donor Study-II (REDS-II), International Component

Abstract

Human T-lymphotropic virus type 1/2 (HTLV-1/2) infection is endemic in Brazil but representative donor prevalence and incidence data are lacking. All blood donations (2007–2009) from three blood centers in Brazil were studied. Samples reactive on one HTLV screening test (EIA) were retested with a different EIA; dual EIA reactivity correlated strongly with a confirmatory Western blot. Prevalence, incidence, and residual transfusion risk were calculated. Among 281,760 first-time donors, 363 were positive for HTLV on both EIAs (135 per 105, 95% CI 122–150). Prevalence differed considerably by region, from 83 to 222 per 105. Overall incidence rate was 3.6/105 person-years and residual transfusion risk was 5.0/106 per blood unit transfused. The logistic regression model showed significant associations with: age [adjusted odds ratio (aOR)=5.23 for age 50+ vs. <20], female sex (aOR=1.97), black (aOR=2.70 vs. white), and mixed skin colors (aOR=1.78 vs. white), and inversely with education (aOR=0.49, college vs. less than high school). HTLV testing with a dual-EIA strategy is feasible and can be useful in areas with low resources. Incidence and residual risk of HTLV-1 transmission by transfusion were relatively high and could be reduced by improving donor recruitment and selection in high prevalence areas. Blood center data may contribute to surveillance for HTLV infection.

Introduction

Human T-lymphotropic virus type 1 (HTLV-1) was the first human retrovirus to be discovered, in 1980, and HTLV-2 was discovered soon afterward, in 1982.1,2 They are usually referred as HTLV-1/2, due to cross-reaction on screening enzyme immunoassays (EIAs). Confirmation of EIA results is necessary with a more specific test such as Western blot (WB), and discriminatory testing is required to differentiate HTLV type (1 and/or 2),3 but both are often not performed in low income countries because of cost.4

Although the exact number of individuals who are seropositive for HTLV-1 and -2 is not known, it is estimated that 15 to 20 million persons are seropositive worldwide, mostly with HTLV-1.5,6 The areas of the world with the highest prevalence rates for HTLV-1 include southwestern Japan, several sub-Saharan African countries, Central and South America,7 and localized areas of Iran and Melanesia.5 In the Americas, higher prevalence rates are found in some countries in the Caribbean, such as Jamaica8 and Trinidad and Tobago. Somewhat lower seroprevalence rates are found in several countries in South America, including Brazil and Colombia.7,9 HTLV-2 is endemic among Amerindians in North, Central, and South America and African Pygmies, and has spread epidemically among injection drug users in North America and Europe.5

The major modes of transmission for both viral types are by sexual contact, from mother to child via breast-feeding, and parenterally by blood transfusion and injection drug use.5,10 Two main diseases have been causally linked to HTLV infection: adult T-cell leukemia/lymphoma (ATL) and HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) are linked to HTLV-15,10 and HAM/TSP only with HTLV-2.11,12 Although these diseases have a relatively low penetrance (5–10% of all infected individuals), they carry high mortality (ATL) and disability (HAM/TSP).10 While the disease spectrum of viruses is not fully known, uveitis and infectious dermatitis have also been associated with HTLV-1, and HTLV-2 has been linked to pulmonary inflammation and increased cancer mortality.1014

HTLV-1/2 infection is endemic in Brazil15,16 and testing blood donors for these viruses is mandatory in the country since 1993. Several studies show that the infection is more prevalent in women and occurs in clusters of higher prevalence.1517 However, recent data from a representative national study of Brazilian blood donors were lacking. We present herein the results of a collaborative study in three blood centers from different geographic regions in Brazil.

Materials and Methods

Population

We studied all blood donations in 2007 through 2009 in three Brazilian blood center databases, combined in a single data warehouse. The participating centers were Fundação Pró-Sangue (FPS) in São Paulo State (Southeast region), Hemominas, in Minas Gerais State (Southeast region), and Hemope in Pernambuco State (Northeast region), as previously described.18 We calculated prevalence in first time blood donors (those who had never donated previously in each center) and incidence among all repeat donors whose previous donation in the blood center was negative. Donor characteristics were recorded at the time of donation; according to common practice in Brazil, skin color was recorded instead of race and ethnicity, and was self-reported. This study was approved by the Federal Committee on Human Subjects (CONEP) of the Ministry of Health in Brazil.

Serological tests

Serum samples were screened with one EIA for HTLV-1/2 [Ortho HTLV-I/HTLVII Ab-Capture ELISA Test System, Raritan, New Jersey; or Abbott Murex HTLV I + II, Dartford, UK]. Samples with EIA optical density to cut-off ratios below 0.9 were considered negative, between 0.9 and 1.1 borderline, and higher than 1.1 positive. Repeatedly reactive samples were sent to the study central laboratory in São Paulo and tested with a second EIA different from the one used for screening [BioMérieux, Vironostika HTLVI/II, Boxtel, The Netherlands; Ortho or Abbot Murex]. For the second EIA the samples were considered either positive or negative, according to the manufacturer`s instructions.

For the year 2007, WBs [HTLV version 2.4, Genelabs Diagnostics (GLD), Singapore] were performed on all samples positive on the second EIA. We also reviewed the WB results for the subset of individuals reactive on the first EIA and negative or borderline on the second EIA, but who returned to the blood center after notification of a positive result and had a confirmatory test performed on that follow-up sample, per blood center routine practice. We used the following manufacturer's criteria to determine final status: “HTLV, type indeterminate” had the presence of p19 and p24 and p21; “HTLV-2” had the presence of p24 and GD21 and rgp46II; “HTLV-1” had the presence of p19 and GD21 and rgp46I; and “Indeterminate” had any band pattern that did not fulfill the above criteria. All laboratory tests used in this study are licensed for routine use in Brazil.

Statistical analysis

Prevalence and 95% confidence intervals for first time donations were calculated by year, sociodemographic characteristics, type of donation, and location. Adjusted odds ratios (aORs) were derived from a logistic regression model. Variables were included in the regression model if they achieved a p-value ≤0.05 in the univariate analysis. While there were 363 donations from FT donors that were positive for HTLV (repeatedly reactive on screening EIAs and reactive on second EIAs), there were an additional 27 donations from FT donors that were repeatedly reactive on screening EIAs but not tested by a second EIA. Based on Fig. 1, among 216 repeatedly reactive screened EIA donations there were 139 positive on second EIA and 77 negative on second EIA. Therefore, we used a 139/216 probability that each of the 27 donations not tested by a second EIA was positive for HTLV to impute data for missing second EIAs.

FIG. 1.
Human T-lymphotropic virus type 1/2 (HTLV-1/2) western blot results according to classification of 2007 calendar year blood donations by the HTLV-1/2 dual enzyme immunoassay (EIA) algorithm. Western blot: HTLV version 2.4, Genelabs Diagnostic.

We computed the incidence rate of HTLV infection per 100,000 person-years by dividing the number of newly identified infections in repeat donors screened in 2007–2009 by the number of person-years of follow-up represented by the interdonation intervals defined by current and previous donation of repeat donors. Unadjusted Poisson regression models were used to compute the 95% confidence intervals around the incidence rates and to assess differences in incidence rates by sociodemographic characteristics, location, and donor type (an adjusted model was not developed due to the small number of incident events). There were nine potential incidents (akin to the 27 potential prevalent cases described above) in which similarly a 139/216 probability was imputed. The pre-REDS-II donation dates were used when available to determine interdonation intervals, and those dates could go back to 1988 for Minas Gerais, 1994 for São Paulo, and 1998 for Recife. Residual transfusion risk was calculated using the incidence and window period model assuming the value of 51 days for the HTLV immunological window and 100% transmission by preseroconversion window-phase donations.19 A two-sided p-value <0.05 was considered to be statistically significant. All statistical tests were performed using SAS 9.2 software (SAS Institute, 2008).

Results

Dual EIAs and WBs were performed on all available samples from HTLV-1/2 primary EIA repeat-reactive donations collected in 2007, and the correlations between dual EIA reactivity and WB results were analyzed (Fig. 1). Of the 291 units detected as initially EIA reactive, 236 were repeatedly reactive and 55 borderline when retested with the same EIA. Of those 216 and 50 were available, respectively, for second EIA and WB testing. Of the 139 samples positive by both assays, 129 were confirmed as positive by WB indicating a positive predictive value (PPV) of the dual EIA testing strategy of 92.8% (95% CI 87.3–96.1) given initial EIA reactivity. Only one case confirmed by WB was positive in the original assay (Abbott) and negative by the second EIA (BioMerieux), yielding a negative predictive value of 99.6% (255/256) (95% CI 97.8–99.9) for the alternate EIA strategy given initial EIA reactivity. With respect to HTLV subtypes, the WB results indicated that of the 113 HTLV-1/2 confirmed positive donors, 103 were HTLV-1 and 10 HTLV-2; hence ~90% of HTLV-1/2 infections among Brazilian donors were HTLV-1.

During the 3-year period of the study (2007–2009) at the three blood centers in Brazil, 281,760 donations were made by first time donors and 637,693 from repeat donors. A total of 363 (128.83/104 donations) of 281,760 first time donations were found to be reactive by both EIAs and therefore considered positive for the purposes of this study (Table 1).

Table 1.
Human T-Lymphotropic Virus Prevalence in First Time Donors by Demographic Characteristics and Type of Donation

Significantly different rates of HTLV prevalence were found in first-time donors by donor age, gender, education status, and race (Table 1). Prevalence increased with age, ranging from a prevalence of 53 per 105 in the <20-years-old group to 386 per 105 in the 50+-year-old group (p<0.0001). Seroprevalence was significantly higher among female (165 per 105) versus male (105 per 105) donors. Analysis by both age and gender revealed increasing HTLV prevalence by age in both genders, rising from 45 per 105 (age <20) to 221 per 105 (age 50+) in men (Chi-square test for trend p<0.0001) and from 62 per 105 (age <20) to 577 per 105 (age 50+) among women (Chi-square test for trend p<0.0001) but with a higher slope in females than in males (Fig. 2).

FIG. 2.
HTLV prevalence rates (positivity based on two EIAs) among Brazilian first-time donors according to age and gender, 2007–2009.

On the other hand, an inverse relationship was observed for education with a higher HTLV prevalence rate of 224 per 105 among those who did not graduate high school versus 75 per 105 among those with a college degree or higher (p<0.001). Prevalence was also higher among those with black skin color (214 per 105) versus mixed (158 per 105) or white (79 per 105) skin color. Prevalence among replacement donors (146 per 105) was not significantly higher than that among community volunteer donors (126 per 105). HTLV prevalence rates differed by region (Table 2), ranging from 83 per 105 in Minas Gerais to 101 per 105 in São Paulo and 222 per 105 in Pernambuco, with little variation over the 3 years of the study.

Table 2.
Human T-Lymphotropic Virus-1/2 Prevalence Among First Time Donors in Three Brazilian Blood Centers, 2007–2009

Center-specific analyses revealed significantly higher HTLV-1/2 prevalence among female first time donors in all blood centers, with the largest difference between the male and female donors seen in Recife, followed by Belo Horizonte and then São Paulo. The highest prevalence rates in the blood centers was found among those with black skin color, followed by the mixed skin color group and then the white skin color group. The highest prevalence in São Paulo was seen among the “other” (nonwhite, nonblack) skin color group. There was also a statistically significant inverse relationship between education level and HTLV prevalence in Recife and São Paulo, but not in Belo Horizonte. The highest prevalence rates were found among those who did not graduate high school, while the lowest rates were seen among those with a college degree or higher.

In the multivariable logistic regression model (Table 3), HTLV-1/2 seropositivity remained significantly associated with location (aOR=1.91 for blood center location at Recife vs. São Paulo), age (aOR=5.23 for age 50+ vs. <20), female sex (aOR=1.97), black (aOR=2.70 vs. white) and mixed skin colors (aOR=1.78 vs. white), and lower education level (aOR=0.49 for college vs. less than high school education).

Table 3.
Correlates of Human T-Lymphotropic Virus Positivity Among First Time Donors Using a Multivariate Logistic Regression Model

The overall incidence rate, i.e., the number of repeat donors who seroconverted for HTLV-1/2 in the study period, was 3.59 per 100,000 person-years (2.61–4.80) for the three blood centers combined (Table 4). Residual risk calculated based on this incidence was 5.0/106 per repeat donor blood units transfused. HTLV incidence rates significantly differed by region, ranging from 1.73 per 105 in São Paulo to 2.82 per 105 in Minas Gerais and 7.16 per 105 in Recife (p<0.01). HTLV incidence significantly differed by gender (p=0.01), with a higher incidence among females (5.74 per 105) versus males (2.78 per 105). HTLV incidence also varied significantly by skin color (p=0.01), with higher rates among those with “other” skin color (15.20 per 105) versus mixed (3.75 per 105) or white (2.40 per 105) or black (0.55 per 105) skin color. Overall, there was no significant difference in the incidence of HTLV by donor type, education, or age.

Table 4.
Human T-Lymphotropic Virus Incidence by Sociodemographic Characteristics, Location, and Donor Type

Discussion

This study, the largest to date among blood donors in Brazil, found HTLV-1 and -2 seroprevalence rates in the order of 1 to 2 per thousand first time donors, which is higher than in the United States and Europe but lower than in the Brazilian general population.2023 Over 90% of the HTLV-1/2 infections were HTLV-1, consistent with previous reports from single centers.6 Previously recognized associations with age, female gender, skin color, and socioeconomic status were confirmed. Broad scale geographic data such as this will allow better monitoring of secular trends in HTLV prevalence by Brazilian blood bankers and public health authorities.

The prevalences found for HTLV-1 and -2 confirm previous studies that Brazil is an endemic country for these viruses.6,15,16 The overall HTLV prevalence found in blood donors from the three centers in Brazil (135.2/105) is comparable to donors in countries in South America5,7,9 and lower than among donors in countries in Central America,8 Caribbean, Africa, Iran, and Melanesia.5,10 It is, however, much higher than those found in blood donors in Europe (2.0–5.0/105), and the United States and Canada (10–30/105).5 In Japan, after introduction of HTLV screening in blood banks, the prevalence in blood donors in the endemic areas dropped considerably.5 It is noteworthy that in many endemic countries in South and Central Americas, the Caribbean region, and Africa, screening for HTLV is not currently performed in all blood banks, although it is transmitted in a very effective way through cellular components of the blood12 and these regions do not perform leukoreduction (removal of leukocytes from donated blood by filtration) routinely, a procedure that could significantly reduce the risk of HTLV transmission through cellular blood components (red blood cell and platelet concentrates).

The associations of HTLV-1/2 seroprevalence with age and gender seen in this study are similar to those reported by other studies in endemic countries. Higher prevalence and increasing slope with age in women compared to men have been attributed to the increased role of sexual transmission in the infection of women.5,11,12 However, increasing prevalence with age has also been attributed to a birth cohort effect in Jamaica, Japan, and the United States,5,8,12,21 namely that younger generations had lower HTLV infection rates than older generations.

The differences in prevalence among the three centers were expected, and probably reflect population origins beyond those reflected in the demographic variables we analyzed. Previous studies show that HTLV-1 tends to concentrate in persons from lower socioeconomic levels, black or mixed skin color, and women.5 Pernambuco State in Northeastern Brazil, where one of the centers (Hemope) is located, has the most notable history among our three centers of imported slave labor from Africa. Both HTLV-1 and sickle cell trait and disease are known to be endemic in Central Africa, and are found at high prevalence in Pernambuco State. São Paulo, which has immigration both from the Northeast region of Brazil and from Japan, a country known for its high prevalence rates of HTLV-1,5 showed in the present study an intermediate prevalence of HTLV-1/2 among blood donors.

There are few incidence data for HTLV-1/2 infection and associated diseases in Brazil and therefore blood services are useful to estimate the incidence of this infection/disease. In the United States, Stramer et al.24 analyzed more than 4.2 million person-years of observation at the American Red Cross during 2008–2009 and found an HTLV incidence rate of 0.3 per 100,000 person-years (95% CI, 0.18–0.52). In the present study, we observed an HTLV incidence of 3.1 per 100,000 person-years during the 3-year study period, 10 times higher than found that in the United States, emphasizing the need for ongoing HTLV testing of blood donors for HTLV in Brazil. A significantly higher incidence in females and those of mixed/other skin color suggests ongoing HTLV transmission in those population subgroups. Interestingly, incidence did not differ with age, suggesting that low-level transmission may continue throughout life in Brazil.

The residual risk for HTLV-1/2 transmission by blood transfusion estimated in the present study (5.0 per million donations) is lower than the 8.6 per million donations risk previously reported from Southern Brazil.24 Still, the risk is strikingly higher than that estimated for Canada (0.95/106) and the United States (0.42/106).24,25 According to the authors of the latter report, such low levels of incidence and residual risk for HTLV may not be low enough to abandon testing of previously screened repeat donors in North America, but should allow reentry of HTLV false-positive individuals to the eligible donor pool.25

Data from blood donors can be extrapolated to other groups, but with caution, since blood donors are selected to be at low risk of parenterally transmissible infections. Data from metropolitan areas of Europe suggest that the seroprevalence of HTLV-1 in pregnant women may be up to 100 times higher than in blood donors.22 Since blood donors come from a relatively healthier stratum of the population, and in the studied centers tend to be younger and males,18 we estimate that the HTLV prevalence in the general population of the Brazilian States where the study was conducted is several times higher, and therefore worthy of public health surveillance. This “sentinel” aspect of the blood banking activity should be emphasized: the reasons for deferring blood donors may point to local health problems and be a “thermometer” of adult population well being.22,26 Blood bank data will also be useful for monitoring secular trends in HTLV prevalence over time.

The dual EIA algorithm we employed, which involves testing each sample that was repeat-reactive with the primary screening EIA using a different EIA, as previously suggested by Seed et al.,27 was shown to have high positive and negative predictive values, and could thus be utilized in blood services that usually do not perform confirmatory tests for HTLV due to the high cost of commercial WBs and unavailability of commercial HTLV PCR tests. This is the case for the majority of blood services in Brazil, where screening for HTLV is obligatory, but not the confirmation. A previous study with PCR analysis of samples from HIV-positive patients from southern Brazil suggested that viral lysate EIAs were less sensitive for HTLV-2, and WB gave indeterminate results for HTLV-2 (particularly subtype 2-b) in Brazil.28 So it is possible that some HTLV-2-infected individuals may not have been detected by the EIAs used in our studies and that some of our WB indeterminates were actually infected with HTLV-2, collectively leading us to underestimate the prevalence of that infection. However, due to differences in the Brazilian region and blood donors versus the HIV patient population, we believe that HTLV-2 prevalence in our study would be only minimally affected by this issue.

The Brazilian public health system, to which HTLV-seropositive donors are referred, is still not prepared to confirm and counsel the donor, therefore creating a difficult public health situation. In some States (e.g., Pernambuco, Bahia, Minas Gerais, Rio de Janeiro) this gap is filled in by research groups that supply the confirmation tests, follow-up with donors and families, and take preventive measures, such as counseling about sexual and mother-to-child transmission. But other States with a very high prevalence (e.g., Maranhão State)6,7 neither do confirmatory tests/follow-up, nor have a researchers and/or public health center to which the donors can be referred.

The strengths of the current study include the inclusion of large numbers of blood donors tested for HTLV antibodies using consistent laboratory procedures. Data on demographic characteristics were also available from a research database formulated from operational blood bank computer systems. Limitations include the lack of specific confirmatory testing on the entire data set, although we believe that the alternate EIA testing strategy is an acceptable alternative for epidemiologic research. We should caution that the positive predictive value of the dual EIA strategy would likely be lower in countries with lower HTLV prevalence than Brazil.

Since approximately 8% of dual EIA reactive donors are not infected based on WB results, we recommend that a WB be performed on dual EIA reactive samples before or in conjunction with donor notification and counseling. Our estimate of residual risk was not adjusted to reflect the approximately 30% rate of transmission associated with refrigerator stored nonleukoreduced RBC components, and hence the reported estimates for residual risk of transfusion transmission of HTLV-1/2 likely are higher than the actual risk. Finally, our operational blood donor database did not include information on sexual behavior or parenteral exposures to allow a detailed assessment of these behavioral risk factors. However, targeted case-control studies would be possible in the future.

In conclusion, we have presented large-scale HTLV seroprevalence and incidence analysis based on screening Brazilian blood donors. We hope to continue to collect similar data in order to monitor secular trends, and to increase the size of the research database by including blood centers from other Brazilian geographic regions. We also plan to monitor HTLV-1/2 incidence, which will allow for a more precise estimation of residual risk of HTLV-1/2 transmission by transfusions in Brazil. Further evaluation of other testing strategies will also be possible using samples collected within this research framework.

Acknowledgments

F. Proietti and A.B. Carneiro-Proietti belong to the Interdisciplinary HTLV Research Group (GIPH). E. Murphy is also supported by NHLBI mid-career award K24-HL-75036. The authors thank the staff at all participating Brazilian blood centers. Without their help, this study would not have been possible.

The Retrovirus Epidemiology Donor Study–II (REDS-II), International Component (Brazil), is the responsibility of the following persons: Blood Centers: Fundação Pró-Sangue/Hemocentro São Paulo (São Paulo)––Ester C. Sabino, Cesar de Almeida Neto, Alfredo Mendrone Jr., Ligia Capuani, and Nanci Salles; Hemominas (Belo Horizonte, Minas Gerais)––Anna Bárbara de Freitas Carneiro-Proietti, Fernando Augusto Proietti, Claudia Di Lorenzo Oliveira, and Carolina Miranda; Fundação Hemope (Recife, Pernambuco)––Divaldo de Almeida Sampaio, Silvana Ayres Carneiro Leão, and Maria Inês Lopes. Data Warehouse: University of São Paulo (São Paulo)––João Eduardo Ferreira, Márcio Oikawa, and Pedro Losco Takecian. U.S. Investigators: Blood Systems Research Institute and University of California San Francisco––M.P. Busch, E.L. Murphy, B. Custer, and T. Gonçalez; Coordinating Center: Westat, Inc.: J. Schulman, M. King, and K. Kavounis; National Heart, Lung, and Blood Institute, NIH: S.A. Glynn.

Author Disclosure Statement

No competing financial interests exist.

References

1. Poiesz BJ. Ruscetti FW. Gazdar AF. Bunn PA. Minna JD. Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 1980;77:7415–7419. [PubMed]
2. Kalyanaraman VS. Sarngadharan MG. Robert-Guroff M. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science. 1982;218:571–573. [PubMed]
3. Wiktor SZ. Alexander SS. Shaw GM. Weiss SH. Murphy EL. Wilks RJ. Shortly VJ. Hanchard B. Blattner WA. Distinguishing between HTLV-I and HTLV-II by Western blot. Lancet. 1990;335:1533. [PubMed]
4. Andrade RG. Ribeiro MA. Namen-Lopes MS. Silva SM. Basques FV. Ribas JG. Carneiro-Proietti AB. Martins ML. Evaluation of the use of real-time PCR for human T cell lymphotropic virus 1 and 2 as a confirmatory test in screening for blood donors. Rev Soc Bras Med Trop. 2010;43:111–115. [PubMed]
5. Proietti FA. Carneiro-Proietti AB. Catalan-Soares BC. Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005;24:6058–6068. [PubMed]
6. Carneiro-Proietti AB. Ribas JG. Catalan-Soares BC. Martins ML. Brito-Melo GE. Martins-Filho OA. Pinheiro SR. Araújo Ade Q. Galvão-Castro B. de Oliveira MS. Guedes AC. Proietti FA. Infection and disease caused by the human T cell lymphotropic viruses type I and II in Brazil. Rev Soc Bras Med Trop. 2002;35:499–508. [PubMed]
7. Carneiro-Proietti ABF. Catalan-Soares BC. Castro-Costa CM, et al. HTLV in the Americas: Challenges and perspectives. Pan Am J Public Health. 2006;19:44–53. [PubMed]
8. Murphy E L. Figueroa J P. Gibbs WN. Holding-Cobham M. Cranston B. Malley K. Bodner AJ. Alexander SS. Blattner WA. Human T-lymphotropic virus type I (HTLV-I) seroprevalence in Jamaica. I. Demographic determinants. Am J Epidemiol. 1991;133:1114–1124. [PubMed]
9. Gotuzzo E. Arango C. de Queiroz-Campos A. Istúriz RE. Human T-cell lymphotropic virus-I in Latin America. Infect Dis Clin North Am. 2000;14:211–239. [PubMed]
10. Gonçalves DU. Proietti FA. Ribas JG. Araújo MG. Pinheiro SR. Guedes AC. Carneiro-Proietti AB. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev. 2010;23:577–589. [PMC free article] [PubMed]
11. Roucoux DF. Murphy EL. The epidemiology and disease outcomes of human T-lymphotropic virus type II. AIDS Rev. 2004;6:144–154. [PubMed]
12. Manns A. Hisada M. La Grenade L. Human T-lymphotropic virus type I infection. Lancet. 1999;353:1951–1958. [PubMed]
13. Biswas HH. Kaidarova Z. Garratty G. Gibble JW. Newman BH. Smith JW. Ziman A. Fridey JL. Sacher RA. Murphy EL. the HTLV Outcomes Study: Increased all-cause and cancer mortality in HTLV-II infection. J Acquir Immune Defic Syndr. 2010;54:290–296. [PMC free article] [PubMed]
14. Murphy EL. Wang B. Sacher RA. Fridey J. Smith JW. Nass CC. Newman B. Ownby HE. Garratty G. Hutching ST. Schreiber GB. Respiratory and urinary tract infections, arthritis, and asthma associated with HTLV-I and HTLV-II infection. Emerg Infect Dis. 2004;10:109–116. [PMC free article] [PubMed]
15. Galvão-Castro B. Loures L. Rodrigues LG, et al. Distribution of human lymphotropic vírus type 1 among blood donors: A nationwide Brazilian study. Transfusion. 1997;37:242–243. [PubMed]
16. Catalan-Soares B. Carneiro-Proietti AB. Proietti FA. GIPH: Heterogeneous geographical distribution of human T cell lymphotropic viruses I and II (HTLV-I/ II): Serological screening prevalence rates in blood donors from large urban areas in Brazil. CSP–Cadernos de Saúde Pública. 2005;21:926–931. [PubMed]
17. Carrazzone CFV. Verçosa AFA. Lorena VMB. Melo MFAD. Machado RCA. Pinto MBDA. Brito AM. Gomes YM. Screening of diseases transmissible by blood in recipients prior to transfusion at a university hospital in the Northeast of Brazil. Rev Brasil Hematol Hemoter. 2006;28:24–27.
18. Carneiro-Proietti ABF. Sabino EC. Sampaio D. Proietti FA. Gonçales TT. Oliveira CDL. Ferreira JE. Liu J. Custer B. Schreiber GB. Murphy E. Busch MP. Demographic profile of blood donors at three major Brazilian blood centers: Results from the International REDS-II study, 2007 to 2008. Transfusion. 2010;50:919–925. [PMC free article] [PubMed]
19. Glynn SA. Kleinman SH. Schreiber GB. Busch MP. Wright DJ. Smith JW, et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991–1996. JAMA. 2000;284:229–235. [PubMed]
20. Schreiber GB. Busch MP. Kleinman SH. Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med. 1996;334:1685–1690. [PubMed]
21. Murphy EL. Watanabe K. Nass CC. Ownby H. Williams A. Nemo G. Evidence among blood donors for a 30-year-old epidemic of human T lymphotropic virus type II infection in the United States. J Infect Dis. 1999;180:1777–1783. [PubMed]
22. Taylor GP. The epidemiology of HTLV-I in Europe. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13(Suppl 1):S8–14. [PubMed]
23. Tseliou PM. Spanakis N. Spiliotakara A. Politis C. Legakis NJ. Tsakris A. HTLV-I and -II in southwestern Greece. Transfusion. 2003;43:1641–1642. [PubMed]
24. Maresch C. Schluter PJ. Wilson AD. Sleigh A. Residual infectious disease risk in screened blood transfusion from a high-prevalence population: Santa Catarina, Brazil. Transfusion. 2008;48:273–281. [PubMed]
25. Chiavetta JA. Escobar M. Newman A. He Y. Driezen P. Deeks S. Hone DE. O'Brien SF. Sher G. Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990–2000. CMAJ. 2003;169:767–773. [PMC free article] [PubMed]
26. Oliveira CDL. Loureiro F. Bastos MRD. Proietti FA. Carneiro-Proietti ABF. Blood donor deferral in Minas Gerais State, Brazil: Blood centers as sentinels of urban population health. Transfusion. 2009;49:851–857. [PubMed]
27. Seed CR. Margaritis AR. Bolton WV. Kiely P. Parker S. Piscitelli L. Improved efficiency of national HIV, HCV, and HTLV antibody testing algorithms based on sequential screening immunoassays. Transfusion. 2003;43:226–234. [PubMed]
28. Morimoto HK. Morimoto AA. Reiche EM. Ueda LT. Matsuo T. Reiche FV. Caterino-de-Araujo A. Difficulties in the diagnosis of HTLV-2 infection in HIV/AIDS patients from Brazil: Comparative performances of serologic and molecular assays, and detection of HTLV-2b subtype. Rev Inst Med Trop São Paulo. 2007;49:225–230. [PubMed]

Articles from AIDS Research and Human Retroviruses are provided here courtesy of Mary Ann Liebert, Inc.